Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PlantPharm BioMed's Hepatitis B oral vaccine is a plant-based, oral solid dose vaccine candidate designed to prevent Hepatitis B virus (HBV) infection. The vaccine utilizes genetically modified plants as biofactories to produce the Hepatitis B surface antigen (HBsAg). Delivered orally as a tablet or capsule, the vaccine is designed to induce both mucosal and systemic immune responses. This platform technology aims to provide a shelf-stable, cost-effective alternative to traditional injectable vaccines, facilitating distribution in resource-limited settings. The candidate has completed an FDA-authorized Phase 1 double-blind human clinical trial, demonstrating equivalence to standard injectable vaccines.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hepatitis B oral vaccine (PlantPharm BioMed).